Regeneron Pharmaceuticals, Inc. (FRA:RGO)
Germany
· Delayed Price · Currency is EUR 535.60
+40.00 (8.07%)
At close: May 2, 2025, 10:00 PM CET
Regeneron Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 13,606 | 13,687 | 12,581 | 11,808 | 15,791 | 7,940 | Upgrade
|
| Other Revenue | 480 | 515 | 536.1 | 365.1 | 281.2 | 557 | Upgrade
|
| Revenue | 14,086 | 14,202 | 13,117 | 12,173 | 16,072 | 8,497 | Upgrade
|
| Revenue Growth (YoY) | 7.52% | 8.27% | 7.76% | -24.26% | 89.14% | 29.58% | Upgrade
|
| Cost of Revenue | 7,212 | 7,103 | 6,255 | 5,153 | 5,298 | 3,767 | Upgrade
|
| Gross Profit | 6,874 | 7,100 | 6,862 | 7,020 | 10,774 | 4,730 | Upgrade
|
| Selling, General & Admin | 2,898 | 2,954 | 2,631 | 2,116 | 1,825 | 1,346 | Upgrade
|
| Other Operating Expenses | - | - | -2.1 | -89.9 | -45.6 | -280.4 | Upgrade
|
| Operating Expenses | 2,898 | 2,954 | 2,629 | 2,026 | 1,779 | 1,066 | Upgrade
|
| Operating Income | 3,975 | 4,145 | 4,233 | 4,994 | 8,995 | 3,665 | Upgrade
|
| Interest Expense | -47.8 | -55.2 | -73 | -59.4 | -57.3 | -56.9 | Upgrade
|
| Interest & Investment Income | 723.4 | 711.4 | 495.9 | 160.1 | 45.8 | 75.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.5 | -0.5 | -12.9 | 50.2 | 0.4 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 24.5 | 15.8 | -20 | 8.8 | 4 | 19.3 | Upgrade
|
| EBT Excluding Unusual Items | 4,675 | 4,817 | 4,623 | 5,154 | 8,988 | 3,702 | Upgrade
|
| Gain (Loss) on Sale of Investments | 453.6 | 117.7 | -237.8 | -39.8 | 386.1 | 196 | Upgrade
|
| Other Unusual Items | -38.1 | -53.4 | - | - | - | - | Upgrade
|
| Pretax Income | 4,984 | 4,780 | 4,199 | 4,859 | 9,326 | 3,810 | Upgrade
|
| Income Tax Expense | 484.9 | 367.3 | 245.7 | 520.4 | 1,251 | 297.2 | Upgrade
|
| Net Income | 4,499 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade
|
| Net Income to Common | 4,499 | 4,413 | 3,954 | 4,338 | 8,075 | 3,513 | Upgrade
|
| Net Income Growth | 16.63% | 11.61% | -8.87% | -46.28% | 129.86% | 66.05% | Upgrade
|
| Shares Outstanding (Basic) | 108 | 108 | 107 | 107 | 106 | 108 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 115 | 114 | 114 | 112 | 115 | Upgrade
|
| Shares Change (YoY) | 0.13% | 1.23% | 0.18% | 1.16% | -2.52% | 0.44% | Upgrade
|
| EPS (Basic) | 41.81 | 40.90 | 37.05 | 40.51 | 76.40 | 32.65 | Upgrade
|
| EPS (Diluted) | 39.43 | 38.34 | 34.77 | 38.22 | 71.97 | 30.52 | Upgrade
|
| EPS Growth | 16.49% | 10.27% | -9.03% | -46.89% | 135.81% | 65.33% | Upgrade
|
| Free Cash Flow | 3,102 | 3,665 | 3,875 | 4,425 | 6,529 | 2,004 | Upgrade
|
| Free Cash Flow Per Share | 27.18 | 31.84 | 34.08 | 38.98 | 58.19 | 17.41 | Upgrade
|
| Gross Margin | 48.80% | 49.99% | 52.32% | 57.67% | 67.04% | 55.67% | Upgrade
|
| Operating Margin | 28.22% | 29.19% | 32.27% | 41.03% | 55.97% | 43.13% | Upgrade
|
| Profit Margin | 31.94% | 31.07% | 30.14% | 35.64% | 50.24% | 41.35% | Upgrade
|
| Free Cash Flow Margin | 22.02% | 25.80% | 29.54% | 36.35% | 40.63% | 23.58% | Upgrade
|
| EBITDA | 4,471 | 4,628 | 4,654 | 5,335 | 9,281 | 3,901 | Upgrade
|
| EBITDA Margin | 31.74% | 32.59% | 35.48% | 43.83% | 57.75% | 45.90% | Upgrade
|
| D&A For EBITDA | 495.7 | 482.9 | 421 | 341.4 | 286.2 | 235.9 | Upgrade
|
| EBIT | 3,975 | 4,145 | 4,233 | 4,994 | 8,995 | 3,665 | Upgrade
|
| EBIT Margin | 28.22% | 29.19% | 32.27% | 41.03% | 55.97% | 43.13% | Upgrade
|
| Effective Tax Rate | 9.73% | 7.68% | 5.85% | 10.71% | 13.41% | 7.80% | Upgrade
|
| Revenue as Reported | 14,086 | 14,202 | 13,117 | 12,173 | 16,072 | 8,497 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.